High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study

Aliment Pharmacol Ther 30, 864–872

[1]  Malte Kelm,et al.  Clinical research for patient empowerment--a qualitative approach on the improvement of heart health promotion in chronic illness. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[2]  G. Rubin,et al.  Review article: medication non‐adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies , 2008, Alimentary pharmacology & therapeutics.

[3]  Jan E. Irvine.  Quality of life of patients with ulcerative colitis: Past, present, and future , 2008, Inflammatory bowel diseases.

[4]  K. Mazzocco,et al.  Risk factors for non‐adherence to medication in inflammatory bowel disease patients , 2007, Alimentary pharmacology & therapeutics.

[5]  Michael P. Jones,et al.  Quality of Life in Patients With Inflammatory Bowel Disease and Irritable Bowel Syndrome Differs Between Subjects Recruited from Clinic or the Internet , 2007, The American Journal of Gastroenterology.

[6]  P. Lakatos,et al.  Nonadherence in inflammatory bowel disease: Results of factor analysis , 2007, Inflammatory bowel diseases.

[7]  E. Kuipers,et al.  Adherence to gastroprotection and the risk of NSAID‐related upper gastrointestinal ulcers and haemorrhage , 2007, Alimentary pharmacology & therapeutics.

[8]  M. Schwab,et al.  Adherence to thiopurine treatment in out‐patients with Crohn’s disease , 2007, Alimentary pharmacology & therapeutics.

[9]  L. Lix,et al.  Predictors of Medication Adherence in Inflammatory Bowel Disease , 2007, The American Journal of Gastroenterology.

[10]  W. D’hoore,et al.  Patient empowerment in theory and practice: polysemy or cacophony? , 2007, Patient education and counseling.

[11]  E. Cabré,et al.  Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease , 2006, Digestive Diseases and Sciences.

[12]  S. Dorn.  Predictors of Crohn's disease. , 2006, Gastroenterology.

[13]  C. Bernstein,et al.  Health care resource utilization in inflammatory bowel disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  S. Kane.  Systematic review: adherence issues in the treatment of ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[15]  K R Abrams,et al.  Long‐term prognosis in Crohn's disease: factors that affect quality of life , 2006, Alimentary pharmacology & therapeutics.

[16]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[17]  A. Francavilla,et al.  A New Oral Delivery System for 5‐ASA: Preliminary Clinical Findings for MMX , 2005, Inflammatory bowel diseases.

[18]  F. Casellas,et al.  Impairment of Health‐Related Quality of Life in Patients With Inflammatory Bowel Disease: a Spanish Multicenter Study , 2005, Inflammatory bowel diseases.

[19]  A. Román,et al.  Adherence to treatment in inflammatory bowel disease. , 2005, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[20]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[21]  M. J. Shale,et al.  Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[22]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[23]  S. Hanauer,et al.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.

[24]  F. Casellas,et al.  Influence of inflammatory bowel disease on different dimensions of quality of life , 2001, European journal of gastroenterology & hepatology.

[25]  S. Grosso,et al.  Psychiatric Predictors of Noncompliance in Inflammatory Bowel Disease: Psychiatry and Compliance , 2001, Journal of clinical gastroenterology.

[26]  C. Rand,et al.  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. , 1999, Medical care.

[27]  E. Lesaffre,et al.  A frequency and correlation analysis of motor deficits in Parkinson patients. , 1998, Disability and rehabilitation.

[28]  S. Hanauer,et al.  An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis , 1996, Annals of Internal Medicine.

[29]  P. Munkholm,et al.  Course of ulcerative colitis: analysis of changes in disease activity over years. , 1994, Gastroenterology.

[30]  S. Lo,et al.  Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.

[31]  J. Paulley,et al.  Reply , 1990, Gut.

[32]  D. Sackett,et al.  Can Simple Clinical Measurements Detect Patient Noncompliance? , 1980, Hypertension.

[33]  A. Thomson.  Patient nonadherence to medication in inflammatory bowel disease. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[34]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.